We partner with the world’s leading pharmaceutical companies and biotechs through our Discovery Forum to unlock genomic data and accelerate new treatment development.
Our Discovery Forum members have access to the following services
Biopharma R&D collaboration
We can support you through the entire drug development journey via bespoke R&D collaborations. Leverage the full set of our capabilities including dedicated bioinformatic support, development of new bioinformatic approaches, patients re-contact at scale, prospective cohort recruitment, and new data generation. Access our rich ecosystem by collaborating directly with leading academic labs and connecting to UK healthcare stakeholders.
Biopharma partners can work with us to recruit retrospective or prospective cohorts of patients that are strategic to their discovery pipelines. We can provide clinical grade WGS, and lifetime follow-up of patient clinical data. Through our partnership with NIHR we can support recruitment through single contract and standard pricing from hospitals throughout England.
All of our participants are consented for re-engagement: specifically, this means we can go back to participants and re-phenotype, re-sample, or recruit these patients onto clinical trials. Genomics England and the NHS impose a high ethical bar before we would re-engage with participants – and we will support our partners in presenting the case, which needs to be ethically, scientifically, and operationally feasible.
Biopharma partners can explore our dataset to find participants with specific clinical phenotypes, view longitudinal phenotypic and clinical data for any participant, and lookup codes in different coding systems such as SNOMED CT, ICD-10, OPCS-4, ICD-O and HPO. All genomics England participants are consented to be re-engaged with and potentially recruited into clinical studies, and this will be done via consultation and clinical review by their lead clinician.
Our research environment already contains a rich set of analytical tools in rare diseases and cancer, which surface aggregate analysis such as variant allele frequency tables, pan tumour SNV signatures, or tumour mutational burden calculations. Our aggregate files of VCFs enables rapid clustering of results and analysis of therapeutic areas. In addition, our expert bioinformatics team can be commissioned to do bespoke analysis through custom consulting projects.
We can support you through the entire drug development journey via bespoke R&D collaborations. Leverage the full set of our capabilities including dedicated bioinformatic support, development of new bioinformatic approaches, patients re-contact at scale, prospective cohort recruitment, and new data generation. Access our rich ecosystem by collaborating directly with leading academic labs and connecting to UK healthcare stakeholders.
Biopharma partners can work with us to recruit retrospective or prospective cohorts of patients that are strategic to their discovery pipelines. We can provide clinical grade WGS, and lifetime follow-up of patient clinical data. Through our partnership with NIHR we can support recruitment through single contract and standard pricing from hospitals throughout England.
All of our participants are consented for re-engagement: specifically, this means we can go back to participants and re-phenotype, re-sample, or recruit these patients onto clinical trials. Genomics England and the NHS impose a high ethical bar before we would re-engage with participants – and we will support our partners in presenting the case, which needs to be ethically, scientifically, and operationally feasible.
Biopharma partners can explore our dataset to find participants with specific clinical phenotypes, view longitudinal phenotypic and clinical data for any participant, and lookup codes in different coding systems such as SNOMED CT, ICD-10, OPCS-4, ICD-O and HPO. All genomics England participants are consented to be re-engaged with and potentially recruited into clinical studies, and this will be done via consultation and clinical review by their lead clinician.
Our research environment already contains a rich set of analytical tools in rare diseases and cancer, which surface aggregate analysis such as variant allele frequency tables, pan tumour SNV signatures, or tumour mutational burden calculations. Our aggregate files of VCFs enables rapid clustering of results and analysis of therapeutic areas. In addition, our expert bioinformatics team can be commissioned to do bespoke analysis through custom consulting projects.
Our ecosystem of partners is very diverse, from top tier biopharma companies to a wide range of genomic-centric biotech and start-ups. As a result, we’re constantly evolving our offering – if you have ideas on how we could develop a partnership together please email us.
